Drug Profile
Sutezolid - Global Alliance for TB Drug Development/Sequella
Alternative Names: PF-02341272; PF-2341272; PNU-100480; U 100480; U 101244; U 101603Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator John Hopkins University; Pharmacia Corporation
- Developer Global Alliance for TB Drug Development; Ludwig-Maximilians-University; Radboud University; Sequella; University of California at San Francisco
- Class Acetamides; Amides; Antibacterials; Oxazolidinones; Small molecules; Thiamorpholines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Tuberculosis
Most Recent Events
- 28 Jul 2023 Phase-II/III clinical trials in Tuberculosis (Combination therapy) in South Africa (PO) (NCT05686356)
- 11 Apr 2023 Radboud University, University of California at San Francisco and University College at London plans a phase II trial (Combination therapy) for Tuberculosis (PO) in Gabon, South Africa, Uganda, Tanzania, Mozambique and Malawi in April 2023 (NCT05807399)
- 20 Jan 2023 Sequella in collaboration with The Aurum Institute and Global Alliance for TB Drug Development plans a phase II/III trial for Tuberculosis (Combination therapy) in Mozambique, South Africa and Tanzania (NCT05686356)